Based on my analysis of the paper and calibration anchors, I can now write the final consolidated review.

---

## Summary
The paper proposes an end-to-end framework for multi-view diabetic retinopathy (DR) grading that eliminates dependence on external lesion annotations. A Grade-Activated Lesion Proposal (GALP) module derives grade-conditioned evidence maps from stage-wise auxiliary classifiers, selecting Top-K spatial regions as self-generated lesion proposals. A Cross-View Lesion Expert-Guided Regional Fusion (LGRF) module then uses gated mixture-of-experts and Top-K-weighted cross-view attention to fuse these proposals across views. Experiments on MFIDDR (4-view) and DRTiD (2-view) show the annotation-free variant matches or surpasses several externally-informed baselines.

---

## Strengths
- **Competitive MFIDDR results without annotations**: The lesion-free variant achieves 83.9% Acc / 70.9% Kappa (Table 1), surpassing LFMVDR-with-lesion (82.2%) and CVSA-with-vessel (82.6%), and closely matching the top externally-informed methods (WGLIN: 84.2%, SMVDR-M: 84.0%). This is a fair comparison — both the proposed method and CVSA use ImageNet-pretrained Swin-B on MFIDDR — and the result substantiates the paper's core claim that self-derived proposals can substitute for external annotations.
- **Internally coherent design**: The GALP→LGRF pipeline has principled consistency: auxiliary classifiers strengthen intermediate features (Eq. 2), their class-specific weights serve as CAMs to localize grade-predictive regions (Eqs. 3–4), and those regions guide cross-view fusion via gated MoE (Eqs. 9–14). The use of LayerCAM-style activation maps as lesion surrogates is grounded in prior literature.
- **Informative hyperparameter analysis**: Figure 3 shows non-trivial sensitivity with clear peaks at α=0.5, K₂=2, M=6 and degradation on both sides, providing substantive empirical guidance rather than cosmetic flat-curve plots.

---

## Weaknesses

### Fatal
None.

### Major
- **Backbone pretraining confound on DRTiD undermines the headline claim there**: For DRTiD, the proposed method uses an EyePACS (fundus)-pretrained Swin-B (Section 4.1: "for DRTiD, the backbone is pretrained on the fundus dataset EyePACS, following CrossFIT"), while all end-to-end baselines the paper surpasses (MVCNN.R/ResNet50, Cv-Transformer, DeepDR, Binocular Network) use substantially weaker architectures with no fundus pretraining. The headline result — "our end-to-end approach achieves the highest overall accuracy, outperforming all existing methods including all externally informed methods" — by a margin of only 0.4 points over CrossFIT (76.0% vs. 75.6%) cannot be attributed to GALP+LGRF versus the substantially stronger pretrained backbone. The paper provides no controlled ablation comparing a strong end-to-end baseline (e.g., MVCNN or CrossFIT) with the same EyePACS-pretrained Swin-B to isolate the module contribution on DRTiD.

- **Ablation does not isolate the lesion proposal mechanism from auxiliary supervision**: In Table 4, "w/o GALP" simultaneously removes both the auxiliary classification loss and the Top-K spatial selection. Since deep supervision via auxiliary classifiers is a well-established technique that could alone explain most of the performance gain, the current ablation cannot distinguish the contribution of the proposal selection mechanism from the benefit of deep supervision. There is no "auxiliary loss only, all tokens fed to LGRF" ablation row, leaving the novel spatial selection mechanism's independent contribution ambiguous.

### Minor
- **Grade 4 clinical failure unacknowledged**: Table 2 shows the proposed method (w/o lesion) achieves only F1=36.0% on Grade 4 (proliferative DR), far below CVSA (64.1%) and below SMVDR-W (40.8%). Proliferative DR is clinically the most severe and actionable grade. The paper mentions "strong Grade 0–3 performance" (Section 4.2) but never discusses this gap or hypothesizes why it occurs (e.g., class imbalance degrading Grade-4-specific CAMs). An undisclosed clinical limitation of this magnitude should be addressed.

- **Cyclic view pairing unjustified**: Cross-view fusion pairs each view only with its cyclically adjacent view (Section 3.3, Eq. 8 logic), so in four-view MFIDDR view 1 never fuses with views 3 or 4. No anatomical motivation or empirical comparison against all-pairs or global cross-view attention is provided.

- **Selectivity framing inconsistent with α=0.5**: The paper claims GALP "recover[s] small, low-contrast lesions" and that Top-K selection "reduces distraction from non-lesion background" (Section 3.2). Yet the retention ratio is fixed at 50% (Section 4.1), meaning half of all spatial cells are retained. At Stage 3 feature maps (7×7 for MFIDDR), this retains ~24 of 49 cells. The "micro-lesion localization" framing overstates the selectivity of retaining half the feature map; the mechanism is better characterized as moderate background attenuation.

### Trivial
None.

---

## Nice-to-Haves
- Add one ablation row: GALP auxiliary loss active, but all tokens (no Top-K filtering) passed to LGRF, to cleanly separate deep supervision from spatial proposal selection.
- Discuss Grade 4 (F1=36%) in a limitations section; hypothesize that class imbalance may degrade auxiliary classifier reliability for Grade 4, producing less localized CAMs.
- For DRTiD, run at least one baseline (e.g., MVCINN or CrossFIT) with the EyePACS-pretrained Swin-B and report; this would confirm or refute the backbone confound.
- Report standard deviation across multiple runs, especially given 0.3–1.2 pp margins between methods.
- Compare cyclic pairing vs. all-pairs fusion as a lightweight ablation.

---

## Removed Points
*These points are flagged as removed — treat with caution.*

1. **Figure 1 "Switch On/Off" framing** (harsh critic): Dismissed as a minor presentation preference. The diagram is broadly accurate and the paper's quantitative results communicate the nuance.

2. **"Ours (with lesion)" architectural distinctness** (harsh critic): The SPADE injection variant is clearly labeled as a separate condition. This is transparent reporting, not a structural confusion.

3. **No variance / confidence intervals** (harsh critic): This is standard practice in the multi-view DR grading community (prior works CVSA, SMVDR, CrossFIT likewise do not report it). Moved to Nice-to-Have.

4. **"w/o LGRF achieves 82.3% and may be competitive" observation**: An informal note about what additional comparisons could be mentioned; not a verifiable weakness.

---

## Novel Insights
The paper's empirical finding that a 50% retention ratio (rather than aggressive selectivity of ~5–10%) yields the best results suggests the primary benefit of GALP may be through its auxiliary classification loss enhancing intermediate feature discriminability rather than through precise lesion localization. This raises the broader question — addressable by the proposed additional ablation — of whether CAM-guided spatial gating provides genuine localization benefit or primarily serves as a regularization of which spatial tokens participate in cross-view attention. Distinguishing these mechanisms would be a meaningful contribution to understanding when self-supervised spatial attention is beneficial in medical imaging.

---

## Suggestions
1. Run the clean-backbone ablation on DRTiD (train MVCINN/CrossFIT with EyePACS Swin-B) and report to disentangle pretraining from architectural contribution.
2. Add the "auxiliary loss + all tokens + LGRF" ablation row to Table 4.
3. Explicitly discuss Grade 4 performance gap in a limitations section.
4. Soften the "micro-lesion localization" narrative to reflect "moderate spatial filtering" given α=0.5.

---

## Score and Decision

**Anchor papers retrieved:**

| Path | Avg Score | Round | Comparison |
|---|---|---|---|
| u1cQYxRI1H.md | 0.50 | R1 | Strong-reject anchor, unrelated illumination paper |
| 5lUdTogEL3.md | 1.00 | R1 | Strong-reject, unrelated re-ID paper |
| EjIKerYk1O.md | 2.33 | R1 | Reject, multi-view aircraft distance estimation; weaker contribution than this paper |
| 8g5Ye3c3oR.md | 4.50 | R1 | Borderline reject, weakly supervised medical lesion segmentation; comparable scope |
| 90z4EDqcmu.md | 4.25 | R1 | Borderline reject, multi-view generation; unrelated domain |
| x1ptaXpOYa.md | 6.50 | R1 | Accept, large-scale document dataset; different type of contribution |
| FUgrjq2pbB.md | 6.50 | R1 | Accept, MVDream multi-view 3D generation; stronger systematic contribution |
| IwgmgidYPS.md | 6.00 | R1 | Accept, large-scale medical dataset; different type |
| 3b9SKkRAKw.md | 8.00 | R1 | Accept, LeFusion lesion-focused diffusion; stronger novelty and evaluation |
| NJxCpMt0sf.md | 5.75 | R2 | Borderline accept, MoE multi-modal multi-task medical; comparable scope and mechanism |
| 33P4evE2ej.md | 4.75 | R2 | Borderline reject, token merging MoE adapters for medical ViT; similar weaknesses |
| yVJd8lKyVX.md | 6.00 | R2 | Accept, MoE multi-label classification; cleaner ablations than this paper |
| Lv9KZ5qCSG.md | 5.50 | R2 | Borderline reject, retinal eye fairness dataset; different contribution type |
| j9DbobO0mY.md | 5.50 | R2 | Borderline reject, MoE retriever for missing modality; incomplete ablations similar to this paper |

**Round 1 bracket**: The paper sits clearly above strong-reject (scores 1–3) territory and below accept-quality papers like MVDream or LeFusion (score 8). The plausible range is **4.5–6.5**, straddling borderline reject and borderline accept.

**Round 2 narrowing**: The most comparable papers are NJxCpMt0sf (MoE multi-modal medical, score 5.75, accepted), 33P4evE2ej (MoE medical adapters, score 4.75, rejected due to incomplete ablations), and j9DbobO0mY (MoE retriever, score 5.5, rejected with mixed reviews). This paper's MFIDDR results are genuinely competitive (fair backbone comparison), the design is sound, and the paper is well-written. However, the DRTiD backbone confound and the incomplete ablation are real issues that parallel what caused 33P4evE2ej and j9DbobO0mY to be rejected. The MFIDDR results alone provide partial but meaningful validation of the core claim. I place this at **5.5**: the contribution is real, the central result on MFIDDR is compelling and fairly compared, but the DRTiD confound and ablation gap are important unresolved issues that prevent a clean accept.

MY FINAL SCORE: <score>5.5</score>
MY FINAL DECISION: <decision>Reject</decision>